Benchtop Bioreactors Market Report 2025

The benchtop bioreactors market size has grown rapidly in recent years. It will grow from $0.98 billion in 2024 to $1.08 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth during the historic period can be attributed to an increasing focus on cell-based research, rising funding for academic and research institutions, growing interest in tissue engineering, expanding use of microbial fermentation processes, and higher adoption in pilot-scale biomanufacturing.

The benchtop bioreactors market size is expected to see rapid growth in the next few years. It will grow to $1.59 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth during the forecast period can be attributed to increasing demand for personalized medicine, the rise of biotechnology startups, growing government investments in biotech infrastructure, expanding adoption of single-use bioreactor systems, and the growth of contract research and manufacturing organizations. Key trends in the forecast period include advancements in sensor and monitoring technologies, enhanced process control and automation features, innovations in single-use bioreactor designs, integration of artificial intelligence and machine learning in bioprocessing, and progress in miniaturized bioprocess systems.

The increasing adoption of gene therapies is expected to drive growth in the benchtop bioreactors market. Gene therapy involves modifying or replacing defective genes to treat or prevent diseases. Demand for gene therapies is rising due to advancements in genetic sequencing and diagnostics, which allow precise identification of disease-causing genes for targeted treatments. Benchtop bioreactors support gene therapies by providing precise control and efficient production of gene-modified cells, enabling rapid research and small-scale manufacturing while improving consistency and process speed. For example, in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, reported that the FDA approved six gene therapy products in 2023, up from five in 2022. Consequently, the growing adoption of gene therapies is fueling the benchtop bioreactors market.

Companies in the benchtop bioreactors market are developing innovative solutions such as benchtop fermenters to enhance precise control and scalability for research and small-scale production. Benchtop fermenters are compact, laboratory-scale bioreactors designed for controlled cultivation of microorganisms or cells. In September 2024, VFL Sciences Private Limited, an India-based biotechnology equipment manufacturer, launched the GreatFlo range of benchtop fermenters. This modular and versatile product line is designed for easy scale-up and reproducible results in fermentation and cell culture applications. The system supports seamless parallel operation with flexible expansion from 2 to 16 vessels, each with a working volume of 200-500 ml. It features Peltier-controlled heating and cooling, exhaust condensers, and 21 CFR Part 11-compliant software, enabling precise control of agitation, pH, dissolved oxygen, and individual gas mixing.

In December 2022, Merck & Co. Inc., a US-based biotechnology company, acquired Erbi Biosystems Inc. for an undisclosed amount. Through this acquisition, Merck aims to strengthen its upstream portfolio in therapeutic proteins by enabling scalable cell-based perfusion bioreactor processes ranging from 2 ml to 2000 liters, accelerate innovation in its process solutions business, and expand development opportunities in novel modalities, including cell therapies. Erbi Biosystems Inc., based in the US, specializes in portable, small-scale bioprocessing bioreactors.

Major players in the benchtop bioreactors market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE Healthcare, Sartorius AG, Eppendorf AG, Solaris Biotech Solutions, IKA-Werke GmbH And Co. KG, GPC Bio USA, Praj HiPurity Systems Limited., PBS Biotech Inc., Bioengineering AG, Broadley-James Ltd., Infors HT, Solida Biotech, Bbi-biotech GmbH, Applikon Biotechnology B.V., Labfirst Scientific Instruments Co. Ltd, Pharsol Ltd., Uma Pharmatech Machinery.

North America was the largest region in the benchtop bioreactors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in benchtop bioreactors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the benchtop bioreactors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Benchtop bioreactors are small-scale laboratory vessels designed for the controlled cultivation of cells, tissues, or microorganisms. They allow precise regulation of environmental parameters such as temperature, pH, and oxygen levels to optimize growth and product yield. These bioreactors facilitate research and development by providing a stable environment for efficient biological processes and product creation.

The primary types of benchtop bioreactors include swing-style bioreactors, stirred-tank bioreactors, wave-mixed bioreactors, airlift bioreactors, and bubble column bioreactors. Swing-style bioreactors employ a rocking or swinging motion to gently mix and aerate cell cultures, offering a controlled setting for cell growth. These bioreactors can be categorized by control type into automated, manual, continuous, and batch systems, and are constructed from materials such as stainless steel, glass, plastic, and composites. They are used in applications such as research and development, process optimization, bioproduction, quality control, and training, serving end users including pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations (CROs), and the food and beverage industry.

The benchtop bioreactors market research report is one of a series of new reports that provides benchtop bioreactors market statistics, including benchtop bioreactors industry global market size, regional shares, competitors with a benchtop bioreactors market share, detailed benchtop bioreactors market segments, market trends and opportunities, and any further data you may need to thrive in the benchtop bioreactors industry. This benchtop bioreactors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The benchtop bioreactors market consists of sales of automated benchtop bioreactors, modular and scalable systems, single-use bioreactors, and micro-bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.